RecruitingNCT07050433

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

COMPASS: Correlative COMPAnion Study to Predict SYNERGY-201 Clinical Trial Responders

Sponsor

Duke University

Enrollment

48 participants

Start Date

Aug 7, 2025

Study Type

OBSERVATIONAL

Conditions

Prostate Cancer

Summary

This study is a companion to the SYNERGY-201 clinical trial (NCT06228053), which investigates SX-682 and enzalutamide in individuals with prostate cancer. Individuals must be participating in SYNERGY-201 in order to participate in this study. The purpose of this companion study is to learn more about biomarkers, particularly a biomarker called CXCR2, and investigate if CXCR2 can predict who will receive benefit from the SYNERGY-201 drug combination. This study will also investigate how CXCR2 and other biomarkers change over time when participants receive the SYNERGY-201 drug combination. CXCR2 is of particular interest because the SYNERGY-201 drug, SX-682, inhibits CXCR2. After participants provide consent, blood samples will be collected for research purposes at three SYNERGY-201 visits (Baseline, Cycle 3 Day 1 and End of Study Drug). Up to 20 participants will also receive tumor biopsies at the Baseline and SYNERGY-201 Cycle 3 Day 1 visits. Clinical and study data collected as part of SYNERGY-201 will also be used for this study.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study collects quality-of-life and treatment outcome data from people with metastatic castration-resistant prostate cancer (prostate cancer that has spread and no longer responds to hormone therapy). It runs alongside another clinical trial called SYNERGY-201. **You may be eligible if:** - You are 18 or older - You are already enrolled in the SYNERGY-201 clinical trial - You are willing to give consent to share your health information **You may NOT be eligible if:** - You have any condition, treatment, or lab result that could interfere with the study or your safety - Your treating physician feels participation is not in your best interest Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.